Flagship Pioneering
VC Fund
Cambridge, United States
Flagship Pioneering is a VC fund in Cambridge focused on Biotechnology and Health Care. Flagship Pioneering conceives, creates, resources, and grows first-in-category ventures to transform human health and sustainability. The company accelerates Flagship Pioneering’s advances in biology, engineering, medicine, energy, and beyond. The firm harnesses science and entrepreneurialism to envision alternative futures, beginning withseemingly unreasonable propositions and navigating to transformational outcomes through an evolutionary methodology.Flagship Pioneering combines innovative capacity, entrepreneurial leadership, and professional capital management in a single enterprise that systematically produces first-in-category companies.
- Total investments:
- 231
- Last investment:
- Lead investor:
- 44%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Flagship Pioneering invests in
Stages Flagship Pioneering invests in
Countries Flagship Pioneering invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $6.5M–$75M
- Series B
- $11M–$230M
- Series C
- $12M–$123M
Investment Focus
Industry
- Biotechnology 64 (28%)
- Health Care 34 (15%)
- Medical 28 (12%)
- Therapeutics 21 (9%)
- Life Science 13 (6%)
Stage
- Series B 47 (20%)
- Series C 38 (16%)
- Series A 36 (16%)
- Funding Round 15 (6%)
- Series D 14 (6%)
Country
- United States 92 (40%)
- Canada 1 (0%)
- United Kingdom 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Geoffrey von Maltzahn
General Partner
|
General Partner | Total investments: 1 | Find email | |
Hari Pujar
Operating Partner
|
Operating Partner | Total investments: 1 | Find email | |
Thomas de Vlaam
Co-Founder FL86
|
Co-Founder FL86 | Total investments: 3 | Find email | |
Avak Kahvejian
General Partner
|
General Partner | Total investments: 7 | Find email | |
Bill Johnson
Vice President of Finance
|
Vice President of Finance | Total investments: 0 | Find email | |
| See all 24 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Serif Biomedicines
|
Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology. Serif combines nucleic acid chemistry, synthetic biology, delivery technology, and artificial intelligence to develop programmable, scalable, long-lasting, and redosable DNA therapies. | $50M / Venture - Series Unknown / Apr 21, 2026 | |
|
Serif Biomedicines
|
Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology. Serif combines nucleic acid chemistry, synthetic biology, delivery technology, and artificial intelligence to develop programmable, scalable, long-lasting, and redosable DNA therapies. | $50M / Venture - Series Unknown / Apr 21, 2026 | |
|
Serif Biomedicines
|
Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology. Serif combines nucleic acid chemistry, synthetic biology, delivery technology, and artificial intelligence to develop programmable, scalable, long-lasting, and redosable DNA therapies. | $50M / Venture - Series Unknown / Apr 21, 2026 | |
Foghorn Therapeutics
|
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter whatour DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases. | $50M / Post-IPO Equity / Jan 09, 2026 | |
Expedition Medicines
|
Expedition Medicine's industry-leading chemoproteomics data generating engine learns the rules of molecular reactivity, enabling programmable small molecule medication design. | $50M / Series A / Oct 22, 2025 | |
Lila Sciences
|
Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method andcontribute to advancements in technology and innovation. | $115M / Series A / Oct 14, 2025 | |
Extuitive
|
Extuitive AI agents develop multiple product and ad versions and select the most effective concepts based on market trends. | $20M / Seed / Sep 18, 2025 | |
|
Lila Sciences
|
Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method andcontribute to advancements in technology and innovation. | $235M / Series A / Sep 14, 2025 | |
Terrana Biosciences
|
Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions. | Jul 01, 2025 | |
|
Terrana Biosciences
|
Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions. | $50M / Series B / Jul 01, 2025 | |
| See all 231 investments → | |||
Co-Investors
Polaris Partners
25 deals together
ARCH Venture Partners
18 deals together
General Catalyst
16 deals together
Alaska Permanent Fund
14 deals together
Invus
14 deals together
Altitude Life Science Ventures
13 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Flagship Pioneering invest in?
Flagship Pioneering invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 231 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Flagship Pioneering's check size?
Flagship Pioneering typically joins rounds of $6.5M–$75M at Series A, $11M–$230M at Series B and $12M–$123M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Flagship Pioneering participates in.
How do I contact Flagship Pioneering?
Public channels for Flagship Pioneering include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Flagship Pioneering?
The team at Flagship Pioneering includes Geoffrey von Maltzahn (General Partner), Hari Pujar (Operating Partner) and Thomas de Vlaam (Co-Founder FL86), among 24 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
